ABSTRACT
INTRODUCTION
The importance of glycemic control for patients with type 2 diabetes has been well documented.
1 Current guidance in both the UK and the US recommends the use of selfmonitoring blood glucose (SMBG) for both insulin and non-insulin treated type 2 diabetes.
2,3
There is, however, continuing debate as to the role of SMBG in the management of patients with non-insulin treated type 2 diabetes. 4, 5 Data from randomized controlled trials are both confusing and contradictory, predominantly due to differences in study design and the inability to measure the impact of SMBG use in isolation to different treatment and management change algorithms. 6, 7 Studies based on observational data are equally inconsistent. A report based on the Fremantle Diabetes Study described no difference in glycosylated hemoglobin (HbA 1c ) between those using SMBG and those who were not, 8 whereas a study based in the United States showed a significant reduction in HbA 1c for those patients newly initiated on SMBG and those patients already using strips treated with either insulin or oral hypoglycemic agents (OA). 9 Furthermore, this study also demonstrated a significant dose response between frequency of SMBG usage and reduction in HbA 1c .
There is a cost to providing SMBG, 4 but this may prove cost-effective when improved management is offset by the reduction of diabetes-related complications. 10 There have also been concerns about the potential negative psychological impact upon patients of using SMBG. 11, 12 However, this has been countered with claims that the use of SMBG allows for the empowerment of patients and enables them to have a greater understanding of their condition and how it is affected by medication and their lifestyle choices. Nevertheless, SMBG use requires the patient and/or carer to act appropriately on the results, otherwise no benefit will accrue.
A previous cohort study by Karter et al. 13 sought to assess the longitudinal association 
MATERIALS AND METHODS

Data Sources
Data used in this study were provided by The Health Improvement Network 14 database, which is a longitudinal research database derived from over 350 primary care practices in the UK and has records for approximately 6 million patients.
15
Inclusion Criteria
The study period was based on 
Cohort Definitions
Patients were classified by SMBG use according to the nomenclature defined by Karter et al., 13 based upon British National Formulary codes recorded in the patient's prescription records.
"Prevalent users" were those with at least one strip prescription before baseline date, and at least two separate prescriptions during the study period. "New users" were those with at least two separate prescriptions in the study period and no strips prescribed in the year before baseline.
"Non-users" were those with no SMBG strips prescribed either before baseline or during the study period.
Patients were also classified according to therapy regimen based upon prescription records using the British National Formulary definitions. The "no medication" group were those patients with no prescriptions (either insulin or OA) recorded in the 90 days before baseline and the final quarter of the study. "OA"
(oral agents only) were those patients prescribed at least one OA and no insulin prescription in the 90 days before baseline and the final quarter of the study. The "insulin" group were those patients prescribed at least one insulin agent, either on its own or in combination with OA at the quarter pre-baseline and the final quarter of the study period. Patients changing their total insulin dosage or OA dosage between these periods were excluded.
Statistical Analysis
Changes in mean HbA 1c before and 12-months post-baseline were compared using the paired were not receiving pharmacological intervention.
The variables were assumed to stand behind the fixed effects, whereas random effects were put on the primary care variable.
RESULTS
From a total of 31,667 patients with type 2 diabetes, 2559 (8.1%) met the inclusion criteria as shown in Figure 1 . Renal failure/ creatinine ≥200 n=82 erapy change n=1800
OA n=1345
Insulin n=271
No medication n=983
Prevalent user n=450
Prevalent user n=246
Prevalent user n=57
New user n=366
New user n=21
New user n=236
Non-user n=529
Non-user n=4
Non-user n=690 This was an observational study based on treatment patterns observed in primary care.
As such it offers a "real world" picture of the impact of SMBG use in everyday practice.
However, we accept that as it did not have the randomization that would occur in a controlled trial there may have been differences between those patients prescribed SMBG and may have confounded our results. Such differences may include patient compliance and motivation and physician preference. However, unlike Karter, 13 in this study we were able to compare patients who remained on the same therapy regimen before and after initiation of SMBG.
Clearly, the motivation to initiate SMBG, either by the patient or physician, will be the need to maintain glycemic control and so may be accompanied by changes in therapy.
Karter et al. 13 highlighted the potential for reverse causality and we noted similar observations in our study-notably that the 
